Business Description
Actinogen Medical Ltd
SIC : 2836
ISIN : AU000000ACW3
Description
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 29.63 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -44.2 | |||||
| 3-Year EPS without NRI Growth Rate | -26 | |||||
| 3-Year FCF Growth Rate | -100 | |||||
| 3-Year Book Growth Rate | -11.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.09 | |||||
| 9-Day RSI | 51.93 | |||||
| 14-Day RSI | 49.37 | |||||
| 6-1 Month Momentum % | -10 | |||||
| 12-1 Month Momentum % | 5.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.91 | |||||
| Quick Ratio | 13.91 | |||||
| Cash Ratio | 6.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.2 | |||||
| Shareholder Yield % | -23.31 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -86.81 | |||||
| ROA % | -77.21 | |||||
| ROIC % | -379.39 | |||||
| ROC (Joel Greenblatt) % | -7599.22 | |||||
| ROCE % | -86.15 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.57 | |||||
| Price-to-Tangible-Book | 1.35 | |||||
| EV-to-EBIT | -5.17 | |||||
| EV-to-EBITDA | -5.34 | |||||
| EV-to-Forward-EBITDA | -5.68 | |||||
| EV-to-Forward-Revenue | 9.28 | |||||
| EV-to-FCF | -4.01 | |||||
| Price-to-Net-Current-Asset-Value | 1.35 | |||||
| Earnings Yield (Greenblatt) % | -19.37 | |||||
| FCF Yield % | -22.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Actinogen Medical Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.003 | ||
| Beta | 3.12 | ||
| Volatility % | 170.84 | ||
| 14-Day RSI | 49.37 | ||
| 14-Day ATR (€) | 0.00065 | ||
| 20-Day SMA (€) | 0.01315 | ||
| 12-1 Month Momentum % | 5.12 | ||
| 52-Week Range (€) | 0.011854 - 0.054 | ||
| Shares Outstanding (Mil) | 3,082.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Actinogen Medical Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Actinogen Medical Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Actinogen Medical Ltd Frequently Asked Questions
What is Actinogen Medical Ltd(FRA:3AC)'s stock price today?
The current price of FRA:3AC is €0.01. The 52 week high of FRA:3AC is €0.05 and 52 week low is €0.01.
When is next earnings date of Actinogen Medical Ltd(FRA:3AC)?
The next earnings date of Actinogen Medical Ltd(FRA:3AC) is .
Does Actinogen Medical Ltd(FRA:3AC) pay dividends? If so, how much?
Actinogen Medical Ltd(FRA:3AC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers